Center-Authored Papers

Filters: Author is Haskell, Charles  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
2009
Tubbs R, Barlow WE, Budd TG, Swain E, Porter PL, Gown A, Yeh I-T, Sledge G, Shapiro C, Ingle J et al..  2009.  Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(24):3881-6. Abstract
2010
Harigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh I-T, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C et al..  2010.  Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome.. The American journal of pathology. 176(4):1639-47. Abstract
Antigens, Neoplasm
Tubbs R, Barlow WE, Budd TG, Swain E, Porter PL, Gown A, Yeh I-T, Sledge G, Shapiro C, Ingle J et al..  2009.  Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(24):3881-6. Abstract
Automation
Harigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh I-T, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C et al..  2010.  Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome.. The American journal of pathology. 176(4):1639-47. Abstract
Breast Neoplasms
Harigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh I-T, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C et al..  2010.  Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome.. The American journal of pathology. 176(4):1639-47. Abstract
Tubbs R, Barlow WE, Budd TG, Swain E, Porter PL, Gown A, Yeh I-T, Sledge G, Shapiro C, Ingle J et al..  2009.  Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(24):3881-6. Abstract
Center-Authored Paper
Harigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh I-T, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C et al..  2010.  Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome.. The American journal of pathology. 176(4):1639-47. Abstract
Tubbs R, Barlow WE, Budd TG, Swain E, Porter PL, Gown A, Yeh I-T, Sledge G, Shapiro C, Ingle J et al..  2009.  Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(24):3881-6. Abstract
Chemotherapy, Adjuvant
Tubbs R, Barlow WE, Budd TG, Swain E, Porter PL, Gown A, Yeh I-T, Sledge G, Shapiro C, Ingle J et al..  2009.  Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(24):3881-6. Abstract
Harigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh I-T, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C et al..  2010.  Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome.. The American journal of pathology. 176(4):1639-47. Abstract
Chromosomes, Human, Pair 17
Tubbs R, Barlow WE, Budd TG, Swain E, Porter PL, Gown A, Yeh I-T, Sledge G, Shapiro C, Ingle J et al..  2009.  Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(24):3881-6. Abstract
Disease-Free Survival
Harigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh I-T, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C et al..  2010.  Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome.. The American journal of pathology. 176(4):1639-47. Abstract
DNA Topoisomerases, Type II
Tubbs R, Barlow WE, Budd TG, Swain E, Porter PL, Gown A, Yeh I-T, Sledge G, Shapiro C, Ingle J et al..  2009.  Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(24):3881-6. Abstract
DNA-Binding Proteins
Tubbs R, Barlow WE, Budd TG, Swain E, Porter PL, Gown A, Yeh I-T, Sledge G, Shapiro C, Ingle J et al..  2009.  Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(24):3881-6. Abstract
Doxorubicin
Tubbs R, Barlow WE, Budd TG, Swain E, Porter PL, Gown A, Yeh I-T, Sledge G, Shapiro C, Ingle J et al..  2009.  Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(24):3881-6. Abstract
Female
Harigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh I-T, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C et al..  2010.  Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome.. The American journal of pathology. 176(4):1639-47. Abstract
Tubbs R, Barlow WE, Budd TG, Swain E, Porter PL, Gown A, Yeh I-T, Sledge G, Shapiro C, Ingle J et al..  2009.  Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(24):3881-6. Abstract
GENE AMPLIFICATION
Tubbs R, Barlow WE, Budd TG, Swain E, Porter PL, Gown A, Yeh I-T, Sledge G, Shapiro C, Ingle J et al..  2009.  Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(24):3881-6. Abstract
Gene Dosage
Tubbs R, Barlow WE, Budd TG, Swain E, Porter PL, Gown A, Yeh I-T, Sledge G, Shapiro C, Ingle J et al..  2009.  Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(24):3881-6. Abstract
Human Biology Division
Harigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh I-T, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C et al..  2010.  Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome.. The American journal of pathology. 176(4):1639-47. Abstract
Tubbs R, Barlow WE, Budd TG, Swain E, Porter PL, Gown A, Yeh I-T, Sledge G, Shapiro C, Ingle J et al..  2009.  Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(24):3881-6. Abstract
Humans
Tubbs R, Barlow WE, Budd TG, Swain E, Porter PL, Gown A, Yeh I-T, Sledge G, Shapiro C, Ingle J et al..  2009.  Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(24):3881-6. Abstract
Harigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh I-T, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C et al..  2010.  Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome.. The American journal of pathology. 176(4):1639-47. Abstract
Immunohistochemistry
Tubbs R, Barlow WE, Budd TG, Swain E, Porter PL, Gown A, Yeh I-T, Sledge G, Shapiro C, Ingle J et al..  2009.  Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(24):3881-6. Abstract
In Situ Hybridization, Fluorescence
Tubbs R, Barlow WE, Budd TG, Swain E, Porter PL, Gown A, Yeh I-T, Sledge G, Shapiro C, Ingle J et al..  2009.  Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(24):3881-6. Abstract